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RESULTS: Varying the compliance rates between 95% and
70% resulted in the average annual drug costs per patient
ranging between $609 and $911 (49.6% difference). Sensi-
tivity analyses of published drug-cost ranges between $400
and $821 for NVF and $800 and $1642 for VF caused av-
erage annual drug costs to vary by 51.8%. Reexamining the
94% compliance assumptions of a recently published report
found that the $1.1 billion estimate for treating HIV/AIDS
in Africa may underestimate costs by more than 28%.
CONCLUSION: Given that studies have demonstrated a
high degree of variability in HIV/AIDS drug compliance
in Africa, future cost studies should examine the impact
of varying compliance rates on their results.
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OBJECTIVE: To outline results of a retrospective analysis
of patient charts at three dermatology clinics in the Neth-
erlands for treatment of external genital warts (EGWs).
METHODS: Patient records with a principal treatment
of EGW were identified. A total of 530 completed epi-
sodes of care for EGWs were analyzed. A (completed) ep-
isode of care was defined as a sequence of visits resulting
in either wart clearance or patient referral to additional
care, typically surgery.
RESULTS: Over 80% of the patients were initially treated
with monotherapy, and podophyllin and cryotherapy were
the principal initial therapy choices. Only 61.7% of males
and 68.4% of females completed an episode of care with
their initial choice of monotherapy. The average total cost of
an episode of care was DFL487.76 and DFL644.13 for males
and females respectively. The cost of achieving a successful
outcome or episode of care (taking into account the propor-
tion of patients with complete and incomplete episode of
care) was DFL872.50 for males and DFL1,068.91 for fe-
males. The cost of completing an episode of care for those
who initiated on podophyllin, taking into account therapy
switching, was DFL451.40 for males (DFL851.48 for fe-
males) compared with DFL426.63 for males initiated on
cryotherapy (DFL372.94 for females) and DFL780.56 for
males initiated on podophyllotoxin (DFL518.57 for females).
CONCLUSION: Podophyllin, although no longer recom-
mended in treatment guidelines, is one of the most fre-
quently used therapies. Costs of treating EGWs are sig-
nificantly impacted by the need to switch.
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OBJECTIVE: To estimate the cost-utility of universal vac-
cination of infants with four doses of a combined 9-valent
conjugated pneumococcal/6-valent outer membrane vesi-
cle meningococcal B/C vaccine in the Netherlands, from a
societal perspective.
METHODS: A decision analysis model is employed to
estimate the health outcomes and costs of the vaccination
program. Data were derived from the Netherlands Refer-
ence Laboratory for Bacterial Meningitis, PRISMANT
Healthcare, national and international literature, and an
expert panel. Direct costs and productivity costs (friction
cost method) are considered. Future costs and QALYs
are discounted at 4%. Cost-utility is expressed as net
costs (in 1998 €) per QALY gained. For the baseline, a
vaccine dose price of €20 and vaccine dose administra-
tion cost of €5 are assumed. The study fully corresponds
with the Dutch guidelines for pharmacoeconomic re-
search.
RESULTS: The vaccination program is estimated to cost
ED18,741,600, to prevent 27 deaths and 16 severe se-
quelae (e.g. seizures, spasticity, and mental retardation),
and to avoid €7,546,600 in expenses per year. It would
render 735 QALYs per year at a cost-utility of €15,200
per QALY. The break-even dose price of the vaccine is
€5.7. These results are sensitive to the vaccine price, the
vaccine effectiveness, and the vaccine coverage against
other meningococcal serosubtypes and pneumococcal se-
rotypes. Excluding the productivity costs has a limited in-
fluence.
CONCLUSIONS: The combination vaccine has not only
a favourable cost-utility ratio when compared to other
vaccines, but also averts a significant number of deaths
and severe sequelae. Therefore it would be a promising
candidate for national immunization programs.
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Clinical trial cost modeling is rarely done, but early pro-
tocol development and cost identification may reduce the
uncertainty surrounding return on investment for thera-
pies such as a new pulmonary TB drug.
OBJECTIVE: To develop a Phase III trial protocol for a po-
tential new pulmonary TB drug and estimate the trial costs.
METHODS: We developed a trial protocol based on the
study design submitted to the Food and Drug Administra-
